Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SSS06

Phase 2Small molecule

SShenyang Sunshine Pharmaceutical Co., LTD.

SSS06 is one of 39 small molecule programs targeting Anemia. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

38

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

AnemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Anemia

#DrugCompanyPhaseTrials

Soliris

Omontys

Jesduvroq

GGlaxo Dba Glaxosmithkline

Epoetin

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Aranesp

Desidustat

ZZydus Lifesciences Limited

Iron Sucrose Injection USP

WWatson Pharmaceuticals

HSK39297

Haisco Pharmaceutical Group Co., Ltd.

CKD-11101

Chong Kun Dang Pharmaceutical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Anemia

NCT06854276

Clinical

Trials by Indication[1]

Anemia1 trial

Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

Not yet recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 2·NCT06854276·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SSS06. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SSS06 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SSS06. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenyang Sunshine Pharmaceutical Co., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShenyang Sunshine Pharmaceutical Co., LTD.

Related News